Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - Corvas International, Inc (NasdaqNM:CVAS)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | SEC | Msgs | Insider | Options | Financials
Location
3030 Science Park Road
San Diego, CA 92121
Phone: (858) 455-9800
Fax: (858) 455-7895
Email: info@corvas.com
Employees (last reported count): 81
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Analyst Upgrade/Downgrade History
 ·Historical Quote Data
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Websites
 ·Home Page
 ·Investor Relations
 ·Employment
 ·Yahoo! Category

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 46%
·Institutional: 53% (98% of float)
(107 institutions)
·Net Inst. Buying: 697.0K shares (+4.57%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
Corvas International, Inc. is a biopharmaceutical company engaged in the discovery, development and commercialization of novel therapeutics that address large markets such as cardiovascular disease, stroke and cancer. The Company has two product candidates in Phase II clinical trials. Its lead product candidate, partnered with Pfizer, is UK-279,276, formerly rNIF, a recombinant protein in Phase IIb clinical trials for the treatment of reperfusion injury associated with ischemic stroke. The Company's second product candidate, rNAPc2, is a recombinant protein that the Company is developing for the prevention of deep vein thrombosis and pulmonary embolism, and for the treatment of unstable angina. The Company also has a number of research programs aimed at developing novel drugs to modulate proteases involved in cancer and other diseases.
More from Market Guide: Expanded Business Description

Financial Summary
Corvas International is engaged in the design and development of a new generation of therapeutic agents in the fields of blood clot formation (thrombosis), inflammation, cancer and other diseases. For the six months ended 6/30/01, revenues decreased 96% to $163 thousand. Net loss totalled $14.1 million, up from $4.5 million. Revenues reflect the contractual end of the collaborative agreements with Schering-Plough. Loss reflects increased R&D due to the manufacturing of rNAPc2.
More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY2000 Compensation
PayExer

M. Blake Ingle, Ph.D., 58
Chairman
--  --  
Randall Woods, 49
Pres, CEO, Director
$498K$1.2M
George Vlasuk, Ph.D., 45
Exec. VP of R&D, CSO, Director
353K893K
Carolyn Felzer, 44
VP, Controller, Assistant Sec.
155K43K
Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year.
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqNM:CVASAs of 31-Aug-2001
Price and Volume
52-Week Low
on 22-Mar-2001
$6.094
Recent Price$7.79 
52-Week High
on 8-Nov-2000
$27.875
Beta0.93 
Daily Volume (3-month avg)323.8K
Daily Volume (10-day avg)83.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y | 5y | max]
52-Week Change-51.3%
52-Week Change
relative to S&P500
-34.7%
Share-Related Items
Market Capitalization$214.0M
Shares Outstanding27.5M
Float14.8M
Dividends & Splits
Annual Dividendnone 
Last Splitnone 
Per-Share Data
Book Value (mrq)$4.06 
Earnings (ttm)-$0.78 
Earnings (mrq)-$0.35 
Sales (ttm)$0.07 
Cash (mrq)$3.46 
Valuation Ratios
Price/Book (mrq)1.92 
Price/EarningsN/A 
Price/Sales (ttm)106.09 
Income Statements
Sales (ttm)$1.86M
EBITDA (ttm)-$24.2M
Income available to common (ttm)-$20.3M
Profitability
Profit MarginN/A 
Operating MarginN/A 
Fiscal Year
Fiscal Year EndsDec 31
Most recent quarter30-June-2001
Management Effectiveness
Return on Assets (ttm)-21.57%
Return on Equity (ttm)-25.50%
Financial Strength
Current Ratio (mrq)17.75 
Debt/Equity (mrq)0.10 
Total Cash (mrq)$95.0M
Short Interest
As of 8-Aug-2001
Shares Short1.12M
Percent of Float7.6%
Shares Short
(Prior Month)
1.26M
Short Ratio2.41 
Daily Volume466.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.